<DOC>
	<DOCNO>NCT00244244</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability arimoclomol ALS patient follow 90 day dose . In addition , amount arimoclomol blood cerebrospinal fluid measure .</brief_summary>
	<brief_title>A Multicenter , Dose Ranging Safety Pharmacokinetics Study Arimoclomol ALS</brief_title>
	<detailed_description>Arimoclomol small molecule upregulates `` molecular chaperone '' cell stress . Arimoclomol extend survival five week give pre-symptomatically disease onset mutant superoxide dismutase ( SOD1 ) transgenic mouse model ALS . Furthermore , demonstrate neuroprotective neuroregenerative effect rat model nerve damage . Molecular chaperone proteins critical cellular response stress protein misfolding . Recent data suggest SOD1 mutation responsible ALS patient familial disease reduces availability variety molecular chaperone , thus weaken ability respond cellular stress . Protein misfolding consequent aggregation may play role pathogenesis familial sporadic form ALS . Therapeutic agent arimoclomol improve cellular chaperone response protein misfolding may helpful ALS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Familial sporadic ALS Vital capacity equal 60 % predict value gender , height age screen visit First ALS symptom occur five year prior screen Must able take oral medication Dependence mechanical ventilation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>